title: Progressive dyspnoea following the treatment of Mycobacterium abscessus infection in an individual with relapsing granulamatosis with polyangitis (Wegener's), complicated by hearing loss requiring cochlear implantation.
abstract: BACKGROUND
  Granulomatosis with polyangitis (Wegener's) is a vasculitic disease predominantly affecting the lungs, skin, kidneys, ears, nose and throat. Mycobacterium abscessus is an uncommon rapidly growing mycobacterium causing sporadic lung disease. This is the first report of both GPA and Mycobacterium abscessus pulmonary disease reported in literature.
  
  
  METHODS
  We present a case report of a 33 year old Caucasian man with relapsing disease complicated by pulmonary infection with Mycobacterium abscessus. He subsequently required bilateral cochlear implantation for progressive sensori-neural hearing loss. His M. abscessus was treated successfully with a prolonged course of antimicrobial therapy. His Granulomatosis with polyangitis (Wegener's) relapsed towards the end of antimicrobial therapy and required treatment. Shortly after completing his antimicrobial therapy and relapse, he developed progressive dyspnea due to pulmonary fibrosis.
  
  
  CONCLUSIONS
  The potential causes of his progressive dyspnoea are discussed including the potential role of his underlying disease and treatment.
authors.affiliation: Internal Medicine & Nephrology Cypress Regional Hospital, Swift Current, Saskatchewan, Canada. senyo2@hotmail.com
authors.forename: Senyo K
authors.initials: SK
authors.lastname: Tagboto
authors.forename: Ajay G
authors.initials: AG
authors.lastname: Venkatesh
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D019929:Cochlear Implantation; D015897:Comorbidity; D003520:Cyclophosphamide / Q000627:therapeutic use; D018450:Disease Progression; D004417:Dyspnea / Q000175:diagnosis / Q000209:etiology*; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy* / Q000453:epidemiology; D034381:Hearing Loss / Q000628:therapy*; D006801:Humans; D008297:Male; D009164:Mycobacterium Infections / Q000188:drug therapy* / Q000453:epidemiology; D011658:Pulmonary Fibrosis / Q000150:complications / Q000453:epidemiology; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab
chemical_list: D000900:Anti-Bacterial Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide